An 11-HSD inhibitor and a derivative of progesterone
Related Products
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

11α-Hydroxyprogesterone

Item No. 35898

Technical Information
Formal Name
11α-hydroxy-pregn-4-ene-3,20-dione
CAS Number
80-75-1
Synonyms
  • 11α-OHP
  • NSC 3350
  • U-0384
Molecular Formula
C21H30O3
Formula Weight
Purity
≥98%
A solid
DMSO: Sparingly Soluble: 1-10 mg/mlEthanol: Sparingly Soluble: 1-10 mg/ml
SMILES
C[C@@]12[C@]3([H])[C@](CCC1=CC(CC2)=O)([H])[C@@]4([H])[C@](C[C@H]3O)([C@H](CC4)C(C)=O)C
InChi Code
InChI=1S/C21H30O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h10,15-19,24H,4-9,11H2,1-3H3/t15-,16+,17-,18+,19+,20-,21+/m0/s1
InChi Key
BFZHCUBIASXHPK-QJSKAATBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    11α-Hydroxyprogesterone (11α-OHP) is an inhibitor of 11β-hydroxysteroid dehydrogenase (IC50s = 0.63 and 0.4 µM for recombinant human 11β-HSD1 and 11β-HSD2, respectively) and a derivative of the endogenous hormone progesterone (Item No. 15876).1,2 11α-OHP (10, 100, and 500 µg/animal) reduces urinary sodium excretion in male adrenalectomized rats when administered in combination with the steroid hormone corticosterone (Item No. 16063) but not when administered alone.1 It potentiates corticosterone-induced increases in urinary potassium excretion in the same model but has no effect on urinary potassium excretion when administered alone. 11α-OHP increases blood pressure in rats when administered subcutaneously at a rate of 10 µg/hour, an effect that can be blocked by adrenalectomy or reduced by co-administration of the mineralocorticoid receptor antagonist RU-28318.3 It has been used as a precursor in the synthesis of various steroids, including 11β-aminoprogesterone and derivatives of 11β-aminoprogesterone and 5ζ-pregnanolone.2,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Souness, G.W., Latif, S.A., Laurenzo, J.L., et al11α- and 11β-hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat. Endocrinology 136(4), 1809-1812 (1995).

    2. Pandya, K., Dietrich, D., Seibert, J., et alSynthesis of sterically encumbered 11β-aminoprogesterone derivatives and evaluation as 11β-hydroxysteroid dehydrogenase inhibitors and mineralocorticoid receptor antagonists. Bioorg. Med. Chem. 21(21), 6274-6281 (2013).

    3. Souness, G.W., and Morris, D.J. 11α- and 11β-hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat. Hypertension 27(3 Pt 1), 421-425 (1996).

    4. Slavíková, B., Bujons, J., Matyáš, L., et alAllopregnanolone and pregnanolone analogues modified in the C ring: Synthesis and activity. J. Med. Chem. 56(6), 2323-2336 (2013).